CITY VIEW GREEN HOLDINGS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED JUNE 30, 2021 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED)

Notice To Reader

The accompanying unaudited condensed interim consolidated financial statements of City View Green Holdings Inc. (the "Company") have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements have not been reviewed by the Company's auditors.

City View Green Holdings Inc.

Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) Unaudited

As at As at June 30. December 31, 2020 2021 ASSETS **Current assets** Cash and cash equivalents \$ 1,355 \$ 152,577 Amounts receivable (note 6) 276,241 275,629 Prepaid rent and deposit 10,311 186,711 Promissory notes receivable (note 7) 497,901 353,066 Total current assets 640,973 1,112,818 Non-current assets Plant and equipment (note 8) 1,373,556 629,167 Right-of-use assets (note 9) 2,660,968 2,825,626 Intangible assets and goodwill (notes 5 and 10) 1,804,217 1,886,818 Investments in associate (note 11) 1,216,476 1,232,872 7,687,301 Total assets 7.696.190 \$ \$ EQUITY AND LIABILITIES **Current liabilities** Accounts payable and accrued liabilities (note 12) \$ 1,192,210 \$ 1,061,116 Loans payable (note 13) 224,082 427,822 Current portion of lease liabilities (note 14) 146.588 137,413 Due to related parties (note 18) 87,943 -**Total current liabilities** 1,650,823 1,626,351 **Non-current liabilities** Loans payable (note 13) 40,000 40,000 Lease liabilities (note 14) 2.882.327 2.957.987 **Total liabilities** 4,573,150 4,624,338 Equity Share capital (note 15) 29,634,398 28,500,186 Shares to be issued (note 5) 1,174,053 1,384,053 Contributed surplus (note 16) 8,125,793 7,794,193 Deficit (35,811,204) (34, 615, 469)Total equity 3,062,963 3,123,040 Total equity and liabilities 7,687,301 \$ 7,696,190 \$

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Nature of operations and going concern (note 1) Subsequent events (note 20)

City View Green Holdings Inc. Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Expressed in Canadian Dollars)

Unaudited

		ree Months Ended June 30, 2021	Three Months Ended June 30, 2020		Ended June 30,		Ended June 30,		Ended June 30,		Ended June 30,		:	Six Months Ended June 30, 2021	-	ix Months Ended June 30, 2020
Expenses																
Consulting (notes 15 and 18)	\$	119,741	\$	318,187	\$	240,560	\$	403,954								
Professional fees	Ŧ	31,223	Ŧ	114,355	Ŧ	53,534	Ŧ	119,116								
Rent		18,713		114,738		30,092		152,866								
General and administration		102,173		5,304		136,647		23,352								
Debt issue costs (notes 13 and 17)		-		46,341		-		77,166								
Share-based compensation (notes 16 and 18)		-		34,120		66,000		175,095								
Depreciation (notes 8 and 9)		233,375		102,551		350,756		209,078								
Advertising and promotion		-		-		1,866		10,619								
Interest on loans and promissory																
notes payable		6,580		40,350		16,731		66,072								
Interest on lease liabilities (note 14)		99,174		112,690		199,423		231,611								
		610,979		888,636		1,095,609		1,468,929								
Net loss before interest and undernoted items		(610,979)		(888,636)		(1,095,609)		(1,468,929)								
Interest income		5,572		6,274		12,222		18,102								
Gain on lease modification (note 14)		-		24,922		-		24,922								
Loss on debt settlement (note 15)		(68,897)		-		(95,952)		-								
Share of gain (loss) in associate (note 11)		-		435,143		(16,396)		166,066								
Net loss and comprehensive loss for the period	\$	(674,304)	\$	(422,297)	\$	(1,195,735)	\$	(1,259,839)								
Basic and diluted net comprehensive																
loss per share (note 19)	\$	(0.00)	\$	(0.00)	\$	(0.00)	\$	(0.01)								
Weighted average number of common shares outstanding - basic and diluted	2	66,278,424	2	04,574,407	2	262,485,018	1	195,486,172								

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

City View Green Holdings Inc. Condensed Interim Consolidated Statements of Cash Flows (Expressed in Canadian Dollars) Unaudited

	Six Months Ended June 30, 2021	Six Months Ended June 30, 2020
Operating activities		
Net loss for the period	\$ (1,195,735)	\$ (1,259,839)
Adjustments for:	· (-,,,	+ (',===;===)
Depreciation	350,756	209,078
Share-based compensation	66,000	175,095
Accrued interest	4,509	22,970
Interest expense on lease liabilities	199,423	231,611
Debt issue cost	-	77,166
Gain on lease modification	-	(24,922)
Loss on debt settlement	95,952	-
Share of loss in associate	16,396	(166,066)
Changes in non-cash working capital items:	-,	())
Amounts receivable	(612)	100,435
Prepaid rent and deposit	176,400	42,295
Accounts payable and accrued liabilities	223,082	157,620
Net cash used in operating activities	(63,829)	(434,557)
Investing activities		
Purchase of plant and equipment	(847,885)	-
Repayment of lease liabilities	(265,908)	(240,000)
Net cash used in investing activities	(1,113,793)	(240,000)
Financing activities		
Proceeds from issuance of units, net of share issue costs	776,400	1,210,000
Proceeds from warrants exercised	5,000	-
Repayment of promissory note	-	(392,367)
Repayment of promissory note receivable	157,057	(72,000)
Advances from related parties	87,943	-
Net cash provided by financing activities	1,026,400	745,633
Net change in cash and cash equivalents	(151,222)	71,076
Cash and cash equivalents, beginning of period	152,577	6,026
Cash and cash equivalents, end of period	\$ 1,355	\$ 77,102

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

City View Green Holdings Inc. Condensed Interim Consolidated Statements of Changes in Equity (Expressed in Canadian Dollars) Unaudited

	Share	Share capital		Share capital						
	Number of shares	Amount		Shares to be issued	C	contributed surplus	Deficit	Total		
Balance, December 31, 2019	186,397,937	\$ 25,987,484	\$	-	\$	3,654,029	\$ (29,003,182) \$	638,331		
Units issued for cash	24,350,000	1,217,500		-		-	-	1,217,500		
Share issuance cost	-	(7,500)		-		-	-	(7,500)		
Fair value of warrants	-	(584,000)		-		584,000	-	-		
Common shares issued for debt settlement	6,970,849	348,542		-		-	-	348,542		
Common shares issued for asset acquisition	9,542,422	477,121		-		-	-	477,121		
Fair value of warrants issued	-	-		-		25,000	-	25,000		
Share-based payments	-	-		-		175,095	-	175,095		
Net loss for the period	-	-		-		-	(1,259,839)	(1,259,839)		
Balance, June 30, 2020	227,261,208	\$ 27,439,147	\$	-	\$	4,438,124	\$ (30,263,021) \$	1,614,250		
Balance, December 31, 2020	247,461,530	\$ 28,500,186	\$	1,384,053	\$	7,794,193	\$ (34,615,469) \$	3,062,963		
Units issued for cash	16,605,000	986,400		(210,000)		-	-	776,400		
Fair value of warrants	-	(268,000)		-		268,000	-	-		
Common shares issued for debt settlement	3,838,097	408,412		-		-	-	408,412		
Issued on exercise of warrants	100,000	7,400		-		(2,400)	-	5,000		
Share-based payments	-	-		-		66,000 [´]	-	66,000		
Net loss for the period	-	-		-		-	(1,195,735)	(1,195,735)		
Balance, June 30, 2021	268,004,627	\$ 29,634,398	\$	1,174,053	\$	8,125,793	\$ (35,811,204) \$	3,123,040		

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

1. Nature of operations and going concern

City View Green Holdings Inc. ("City View" or the "Company") was incorporated pursuant to the Canada Business Corporations Act on February 5, 2008. The Company continued into British Columbia from the jurisdiction of Canada, under the BCBCA, on February 18, 2011. On February 27, 2019, the Company completed a reverse take-over business combination with 2590672 Ontario Inc. ("2590672 Ontario") wherein the Company acquired 100% of the issued and outstanding common shares of 2590672 Ontario and began trading on the Canadian Securities Exchange ("Exchange") under the symbol "CVGR".

These unaudited condensed interim consolidated financial statements reflect the continuation of the financial position, operating results and cash flows of the Company's legal subsidiary, 2590672 Ontario.

The unaudited condensed interim consolidated financial statements have been prepared using accounting policies applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they become due. As at June 30, 2021, the Company is still in the development stage, has accumulated losses of \$35,811,204 since its inception and expects to incur further losses in the development of its business. These conditions raise material uncertainties which cast significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. While the Company is continuing its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds for operations. The unaudited condensed interim consolidated financial statements do not reflect adjustments to the carrying values and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern, and such adjustments may be material.

On April 30, 2021, the Company received the cannabis processing license from Health Canada. The processing license allows the Company to produce cannabis edibles and related products and will allow the Company to conduct development activities, including the formulation of proprietary cannabis infused edibles.

The Company's operations could be significantly adversely affected by the effects of a widespread global outbreak of a contagious disease, including the recent outbreak of respiratory illness caused by COVID-19. The Company cannot accurately predict the impact COVID-19 will have on its operations and the ability of others to meet their obligations with the Company, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect the Company's operations and ability to finance its operations.

2. Basis of presentation

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by IASB and interpretations issued by IFRIC.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRSs issued and outstanding as of August 30, 2021, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual financial statements as at and for the year ended December 31, 2020. Any subsequent changes to IFRS that are given effect in the Company's annual financial statements for the year ending December 31, 2021 could result in restatement of these unaudited condensed interim consolidated financial statements.

3. Significant accounting judgments, estimates and assumptions

The preparation of the consolidated financial statements using accounting policies consistent with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. The preparation of the consolidated financial statements also requires management to exercise judgment in the process of applying the accounting policies.

Critical accounting estimates

Impairment of plant and right-of-use assets - assessing whether indicators of impairment exist at reporting period ends and, if required, determining recoverable amounts including assumptions and inputs thereto.

Share-based compensation – management is required to make a number of estimates when determining the compensation expense resulting from share-based transactions, including the forfeiture rate and expected life of the instruments.

Warrants – management is required to make a number of estimates when measuring the value of warrants including the forfeiture rate and expected life of the instruments.

Plant and right-of-use assets - management is required to estimate the useful lives and residual value of property, plant and equipment which are included in the consolidated statements of financial position and the related depreciation included in the consolidated statements of loss.

Intangible assets – The Company applies judgment to assess whether there are any indications that its intangible assets may be impaired. This assessment requires an assessment of external, internal and other indicators at the end of each reporting period.

Recoverability of promissory notes receivable – Management's assessment of whether indicator of write off the receivable are present requires judgment based on facts and circumstances at reporting period ends.

3. Significant accounting judgments, estimates and assumptions (continued)

Critical judgments in applying accounting policies

Income taxes – measurement of income taxes payable and deferred income tax assets and liabilities requires management to make judgments in the interpretation and application of the relevant tax laws. The actual amount of income taxes only become final upon filing and acceptance of the tax return by the relevant authorities, which occurs subsequent to the issuance of the consolidated financial statements.

Going concern – the assessment of the Company's ability to continue as a going concern involves judgment regarding future funding available for its operations and working capital requirements as discussed in note 1.

Impairment assessment of investment in associate – Management's assessment as to whether there is any objective evidence that its net investment in the associate is impaired. Management must determine whether there has been a loss event that has an impact of the estimated future cash flows from the net investment that can be reliably estimated. Objective evidence that the net investment is impaired includes observable data that comes to the attention of the entity.

4. Capital risk management

The Company manages its capital with the following objectives:

- to ensure sufficient financial flexibility to achieve the ongoing business objectives including funding of future growth opportunities; and
- to maximize shareholder return through enhancing the share value.

The Company monitors its capital structure and makes adjustments according to market conditions in an effort to meet its objectives given the current outlook of the business and financial markets in general. The Company may manage its capital structure by issuing new shares, repurchasing outstanding shares, or adjusting spending. The capital structure is reviewed by management and the Board of Directors on an ongoing basis.

The Company considers its capital structure to consist of share capital, contributed surplus, and deficit, which at June 30, 2021 totaled \$3,123,040 (December 31, 2020 - \$3,062,963). The Company reviews its working capital and forecasts its future cash flows based on operating expenditures, and other investing and financing activities. Selected information is provided to the Board of Directors of the Company. The Company is not subject to any capital requirements imposed by a lending institution.

5. Asset acquisition

On April 30, 2020, the Company closed an asset purchase transaction (the "Asset Purchase Transaction") with Infusion Works Inc. ("Infusion Works"). The Asset Purchase Transaction involved the acquisition of certain know-how, intellectual property and machinery related to food manufacturing, including baked goods, chocolates and other confectionary products containing various cannabinoids.

Pursuant to the Asset Purchase Transaction, the Company acquired equipment for the production of cannabis-infused food products including certain intellectual property related to the production thereof. In addition, Infusion paid a deposit of \$439,238 (the "Deposit") to the Company to be used towards the purchase of certain new food manufacturing equipment and shall assign to City View the economic benefit of all existing contracts and future contracts or the contracts themselves at the time the Company receives the Licence (as defined hereinbelow).

In consideration, the Company will issue to Infusion an aggregate of 46,462,114 common shares in the capital of the Company ("Consideration Shares") issuable in three tranches, subject to an adjustment (the "Adjustment"). The first tranche was issued on April 30, 2020 and consisted of 9,292,422 shares. The second tranche was issued on October 26, 2020 upon receipt by the Company of the Deposit and consisted of 13,938,634 shares. The third and final tranche (the "Third Tranche") shall be issued upon the receipt by the Company of a Health Canada licence under the Cannabis Act (the "Licence") and shall consist of 23,231,057 shares. Pursuant to the Adjustment, at the time of Third Tranche, the Company will issue to Infusion such number of shares equal to 19.99% of the amount by which the issued and outstanding number of shares on the date of issuance of the third tranche shares exceeds 257,276,785. Moreover, the Company and Infusion have entered into a profit sharing agreement pursuant to which the Company shall pay to Infusion 10% of its EBIT for a period of 3 years commencing on the date of receipt of the Licence, payable in shares at a price equal to the 15 day volume weighted average price of the shares on the CSE prior to the applicable period.

In connection with the Transaction, the Company and Infusion have each paid a finder a finder fee of 500,000 shares, for a total of 1,000,000 shares issuable in two equal tranches. The first tranche of the finders shares was paid on April 30, 2020 and the second tranche of finder shares shall be paid at the time of the Third Tranche.

The purchase price allocation of the assets acquired is as follows:

Cash Equipment Intangible assets and goodwill	\$	439,238 36,360
Testing/formation technology		864,310
Standard operating procedures		61,750
Contracts		560,758
Goodwill		400,000
	\$	2,362,416
Consideration given		
First tranche - 9,292,422 common shares (issued)	\$	464,621
Finder fees (first tranche) - 250,000 common shares (issued)	·	12,500
Second tranche - 13,938,634 common shares (issued)		696,932
Third tranche - 23,231,057 common shares		1,161,553
Finder fees (second tranche) - 250,000 common shares		12,500
Transaction costs		14,310
	\$	2,362,416

Unaudited

6. Amounts receivable

	As at June 30, 2021	De	As at December 31, 2020		
Sales tax receivable - Canada (i) Amounts receivable	\$ 196,626 79,615	\$	221,014 54,615		
	\$ 276,241	\$	275,629		

(i) Sales tax receivable is not past due.

7. Promissory notes receivable

(i) On March 5, 2019, the Company entered into a loan agreement in the amount of \$200,000 with 11103016 Canada Inc. ("11103016 Canada"). The loan is secured by 11103016 Canada's inventory and equipment, and bears interest rate of Prime Bank Rate plus 5% per annum, calculated monthly not in advance. The loan is repayable on or before March 5, 2020. The Company loaned an additional \$100,000 to 11103016 Canada in August 2019. On March 5, 2020, the Company extended the repayment date of the loan to December 31, 2020. In April 2021, the repayment date was extended to December 31, 2021.

As at June 30, 2021, the Company was owed \$353,066 (December 31, 2020 - \$341,983) including accrued interest.

(ii) In April 2019, the Company entered into a loan agreement with Budd Hutt, whereby the Company can advance up to \$400,000 per year to Budd Hutt by way of a single loan or multiple loans. On April 12, 2019, the Company advanced \$50,000. The loan bears interest rate of 8% per annum, calculated monthly not in advance. The loan is repayable on or before April 12, 2020. The Company loaned an additional \$94,000 during the year ended December 31, 2020.

During the six months ended June 30, 2021, Budd Hutt fully repaid \$157,057, including accrued interest.

Unaudited

8. Plant and equipment

Cost		easehold rovement	s E	quipment		Total
Balance, December 31, 2019 Additions (note 5)	\$	306,881 341,672	\$	- 133,376	\$	306,881 475,048
Balance, December 31, 2020 Additions		648,553 198,525		133,376 649,360		781,929 847,885
Balance, June 30, 2021	\$	847,078	\$	782,736	\$	1,629,814
Accumulated depreciation		easehold rovement	s E	quipment		Total
Balance, December 31, 2019 Depreciation for the year	\$	58,302 94,460	\$	-	\$	58,302 94,460
Balance, December 31, 2020 Depreciation for the period	\$	152,762 77,406	\$	- 26,091	\$	152,762 103,497
Balance, June 30, 2021	\$	230,168	\$	26,091	\$	256,259
Carrying value		easehold rovement	s E	quipment		Total
Balance, December 31, 2020 Balance, June 30, 2021	\$ \$	495,791	\$ \$	133,376 756,645	\$ \$	629,167

Right-of-use assets 9.

Cost	Brantford facility
Balance, December 31, 2019	\$ 3,647,330
Modification of lease (note 14(i)) Balance, December 31, 2020 and June 30, 2021	(330,943) \$ 3,316,387
Accumulated depreciation	Brantford facility
Balance, December 31, 2019 Depreciation for the year	\$ 151,972 338,789
Balance, December 31, 2020 Depreciation for the period	\$ 490,761 164,658
Balance, June 30, 2021	\$ 655,419
Carrying value	Brantford facility
Balance, December 31, 2020 Balance, June 30, 2021	\$ 2,825,626 \$ 2,660,968

Intangible assets and goodwill 10.

Cost	fo	esting/ ormation chnology	0	tandard perating pcedures	C	ontracts		Goodwill		Total
0051	101	mology	рг		<u> </u>			Cocamin		Total
Balance, December 31, 2019	\$	-	\$	-	\$	-	\$	-	\$	-
Additions (note 5)	•	864,310	Ŧ	61,750	Ŧ	560,758	Ŧ	400,000		1,886,818
Balance, December 31, 2020 and June 30, 2021		864,310		61,750		560,758		400,000		1,886,818
Accumulated depreciation	fo	esting/ ormation chnology	0	tandard berating bcedures	С	ontracts		Goodwill		Total
Balance, December 31, 2019 and										
December 31, 2020	\$	-	\$	-	\$	-	\$	-	\$	-
Depreciation for the period	Ŧ	48,017	Ŧ	3,431	Ŧ	31,153	Ŧ	-	Ŧ	82,601
Balance, June 30, 2021	\$	48,017	\$	3,431	\$	31,153	\$	-	\$	82,601
Carrying value	Testing/ formation technology		Standard operating procedures		С	ontracts		Goodwill		Total
Balance, December 31, 2020	\$	864,310	\$	61,750	\$	560,758	\$	400,000	\$	1,886,818
Balance, June 30, 2021	\$	816,293	\$	58,319	\$	529,605	\$	400,000		1,804,217

11. Investment in associate

On November 5, 2018, the Company entered into an agreement with Budd Hutt whereby the Company and Budd Hutt will conduct a mutual share exchange consisting of the Company owning 19.9% of Budd Hutt, and Budd Hutt owning 19.9% of the Company. In connection with this transaction, the Company issued 29,968,427 shares valued at \$0.19 per share. The transaction closed on January 31, 2019.

On September 30, 2019, the Company acquired an additional 500,000 common shares of Budd Hutt with a deemed value of \$0.20 per share to settle \$100,000 of balance owed (see note 7). As a result, the Company owns 27.5% of Budd Hutt.

The Company has accounted for the transactions below as an investment in Budd Hutt, with an initial aggregate acquisition cost carrying value in the amount of \$5,719,080 (December 31, 2020 - \$5,719,080), and will follow equity accounting, with a provision for write-downs, if required, in the future. Management determined that the Company has significant influence over these investments. The Company continues to review the accounting treatment for this investment and will make any adjustment in the future as required under IFRS.

		D	As at ecember 31, 2020	
Acquisition costs Share of loss in associate Impairment loss from investment in associate	\$	5,719,080 (337,068) (4,165,536)	\$	5,719,080 (337,068) (4,149,140)
	\$	1,216,476	\$	1,232,872

The following is a summary of the financial information of Budd Hutt on a 100% basis as at the specified date and for the period then ended, as disclosed in the table below, which is the most recent publicly available information for Budd Hutt. The information is pursuant to Budd Hutt's management prepared (unaudited) financial statements as at and for the three and six months ended June 30, 2021.

					As a June 3 2021	30,	De	As at cember 31, 2020
Cash Due from the Company Total current assets Total non-current assets Loans payable to the the Company Total current liabilities				\$	42 22 ² 3,58	2,579 2,943 1,330 5,816 6,488)	\$	- 165,808 3,182,816 (155,918) (3,498,344)
		ee Months Ended June 30, 2021	Tł	nree Months Ended June 30, 2020	E	Months Ended une 30, 2021	-	ix Months Ended June 30, 2020
Net income (loss) Proportionate share of net income (loss)	\$ \$	(59,622) (16,396)	\$ \$	1,582,336 435,143	\$ \$	(59,622) (16,396)	-	603,876 166,066

12. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities of the Company are principally comprised of amounts outstanding for purchases relating to general operating activities.

	As at June 30, 2021	De	As at ecember 31, 2020
Accounts payable	\$ 1,079,710	\$	917,805
Accrued liabilities	112,500		143,311
Total accounts payable and accrued liabilities	\$ 1,192,210	\$	1,061,116

13. Loans payable

(i) On July 7, 2020, the Company entered into a revolving line of credit agreement (the "LOC Agreement") with a third party lender ("Lender"), whereby the Company can obtain \$1,500,000 of revolving line of credit financing facility to be used exclusively for the purchase of the Company's business related equipment, deposits for construction work and tenant's improvement on the Company's Brantford facility, or for security, rental payments, taxes and insurance related thereto. The funds advanced under the LOC bear interest at a rate of 10% per annum, and the LOC Agreement was amended to terminate on July 7, 2021. The Company is currently negotiating an extension to the maturity date to December 31, 2021.

In consideration for lending the funds advanced, the Company is to issue to the Lender one unit of the Company for each full \$1 advanced. Each unit will consist of one common share of the Company and one common share purchase warrant. Each warrant shall entitle the Lender to purchase one common share of the Company at the greater of \$0.15 and a 25% premium to the market price of the Company's common shares at the time of issuance and expire in 2 years.

During the six months ended June 30, 2021, the Company issued 2,755,900 common shares to settle \$220,472 of the LOC. As at June 30, 2021, the Company owed \$224,082 (December 31, 2020 - \$427,822) including accrued interest.

(ii) In April 2020, the Company received \$40,000 under the Canada Emergency Business Account (CEBA) program. 25% of the loan is forgivable if repaid by December 31, 2022. The loan accrues no interest until December 31, 2022, and thereafter converts to a 3-year term loan with a 5% annual interest rate. Any portion of the loan is repayable without penalty at any time prior to December 31, 2025

City View Green Holdings Inc.

Notes to Condensed Interim Consolidated Financial Statements Three and Six Months Ended June 30, 2021 (Expressed in Canadian Dollars) Unaudited

14. Lease liabilities

	Brantford facility
Balance, December 31, 2019	\$ 3,674,360
Modification of lease (i)	(554,663)
Interest expense	421,339
Lease payments	(445,636)
Balance, December 31, 2020	\$ 3,095,400
Interest expense	199,423
Lease payments	(265,908)
	3,028,915
Less: current portion	(146,588)
Balance, June 30, 2021	\$ 2,882,327

(i) During the year ended December 31, 2020, the Company negotiated with its landlord who has agreed to reduce the monthly rent payable at the Brantford facility to \$25,000 from April to September 2020 and \$44,318 from October 2020 to October 2024.

15. Share capital

(a) Authorized share capital

Unlimited number of common shares, with no par value.

(b) Common shares issued

	Number of common shares	Amount
Balance, December 31, 2019	186,397,937	\$ 25,987,484
Units issued for cash (i)	24,350,000	1,217,500
Share issuance cost (i)	,,	(7,500)
Fair value of warrants (i)	-	(584,000)
Common shares issued for debt settlement (ii)	6,970,849	348,542
Common shares issued for asset acquisition (note 5)	9,542,422	477,121
Balance, June 30, 2020	227,261,208	\$ 27,439,147
Balance, December 31, 2020	247,461,530	\$ 28,500,186
Units issued for cash (iii)(v)	11,400,000	570,000
Fair value of warrants (iii)(v)	-	(155,000)
Common shares issued for debt settlement (iv)(vi)	1,082,197	119,042
Issued on exercise of warrants	100,000	7,400
Balance, June 30, 2021	260,043,727	\$ 29,041,628

15. Share capital (continued)

(b) Common shares issued (continued)

(i) During April - June 2020, the Company completed non-brokered private placement in 3 tranches, pursuant to which it issued an aggregate of 24,350,000 units in the capital of the Company at a price of \$0.05 per unit for aggregate gross proceeds of \$1,217,500. Each unit is composed of one common share of the Company and one share purchase warrant. Each warrant entitles the holder to purchase one share at a price of \$0.05 per warrant for a period of 3 years from the date of issuance, subject to an acceleration provision whereby, after one year from their date of issuance, if the closing price of the shares on the CSE is equal to or exceeds \$0.15 for a period of 10 consecutive trading days, then the Company may, at its option, accelerate the expiry date of the warrants to the date which is 30 days following the date upon which notice of the accelerated expiry date is provided by the Company to the holders of the warrants. The Company incurred share issuance cost of \$7,500.

The 24,350,000 warrants issued were assigned a value of \$584,000 using the Black-Scholes valuation model using the following assumptions: weighted average share price of \$0.026, risk-free rate of return of 0.28%, expected volatility of 220% based on historical trends, dividend yield of 0%, and expected life of 3 years.

- (ii) On June 17, 2020, the Company issued 6,970,849 common shares to certain creditors of the Company to settle an aggregate debt of \$348,542. The common shares issued had a deemed price of \$0.05 based on the fair value.
- (iii) On January 8, 2021, the Company completed the second and final tranche of its non-brokered private placement, pursuant to which it issued an aggregate of 11,400,000 units for aggregate gross proceeds of \$570,000. Each unit is composed of one common share of the Company and one half share purchase warrant. Each warrant entitles the holder to purchase one share at a price of \$0.05 per warrant for a period of 2 years from the date of issuance, subject to an acceleration provision whereby, after four months and one day from their date of issuance, if the closing price of the shares on the CSE is equal to or exceeds \$0.15 for a period of 10 consecutive trading days, then the Company may, at its option, accelerate the expiry date of the warrants to the date which is 30 days following the date upon which notice of the accelerated expiry date is provided by the Company to the holders of the warrants. The Company did not incur any share issuance costs.

The 5,700,000 warrants issued were assigned a value of \$155,000 using the Black-Scholes valuation model using the following assumptions: weighted average unit price of \$0.05, risk-free rate of return of 0.19%, expected volatility of 200% based on historical trends, dividend yield of 0%, and expected life of 2 years.

- (iv) On January 29, 2021, the Company issued 1,082,197 common shares to certain creditors of the Company to settle an aggregate debt of \$91,987. The common shares issued had a deemed price of \$0.11 based on the fair value and as a result, the Company recognized a loss on settlement of debt of \$27,055.
- (v) In April 2021, the Company completed a non-brokered private placement, pursuant to which it issued an aggregate of 5,205,000 units for aggregate gross proceeds of \$416,400. Each unit is composed of one common share of the Company and one half share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at a price of \$0.15 per share for a period of 2 years from the closing date, subject to acceleration from and after the date that is fourth months and one day after the closing date, if the closing price of the Company's common shares on the CSE is equal to or exceeds \$0.20 for 10 consecutive trading days, at which time the Company may accelerate the expiry date of the warrants to the date that is 30 following the date on which the Company issues notice to all the warrant holders of the new expiry date.

The 2,602,500 warrants issued were assigned a value of \$113,000 using the Black-Scholes valuation model using the following assumptions: unit price of \$0.08, weighted average risk-free rate of return of 0.26%, expected volatility of 196% based on historical trends, dividend yield of 0%, and expected life of 2 years.

15. Share capital (continued)

(b) Common shares issued (continued)

(vi) On April 30, 2021, the Company issued 2,755,900 common shares to settle \$220,472 of the LOC (note 13(i)). The common shares issued had a deemed price of \$0.105 based on the fair value and as a result, the Company recognized a loss on settlement of debt of \$68,897.

16. Stock options

The Company has a Share Option Plan (the "Plan") under which it is authorized to grant options to purchase common shares of the Company to directors, senior officers, employees and/or consultants of the Company. The aggregate number of shares of the Company which may be issued and sold under the Plan will not exceed 15% of the total number of common shares issued and outstanding from time to time. Share options are granted with a maximum term of ten years with vesting requirements at the discretion of the Board of Directors.

Company records a charge to the statement of loss and comprehensive loss using the Black-Scholes fair valuation option pricing model with respect to a share option grant. The valuation is dependent on a number of estimates, including the risk free interest rate, the level of share volatility, together with an estimate of the level of forfeiture. The level of share volatility is calculated with reference to the historic traded daily closing share price at the date of issue. Option pricing models require the input of highly subjective assumptions including the expected price volatility. Changes in the subjective input assumptions can materially affect the fair value estimate, and therefore the existing models do not necessarily provide a reliable measure of the fair value of the Company's share purchase options.

	Number of stock options	Weighted average exercise price		
Balance, December 31, 2019	19,119,732	\$	0.36	
Cancelled	(3,450,000)		0.45	
Balance, June 30, 2020	15,669,732		0.34	
Balance, December 31, 2020	29,789,732	\$	0.23	
Granted (i)	600,000		0.12	
Balance, June 30, 2021	30,389,732	\$	0.22	

(i) On February 18, 2021, the Company granted 600,000 stock options to consultants of the Company exercisable at \$0.12 per common share. The options vest immediately and expire in 3 years. The grant date fair value of \$66,000 was assigned to the stock options as estimated by using the Black-Scholes valuation model with the following assumptions: share price of \$0.12, expected dividend yield of 0%, expected volatility of 200%, risk-free rate of return of 0.27% and an expected maturity of 2 years. For the three and six months ended June 30, 2021, \$66,000 (three and six months ended June 30, 2020 - \$nil) was expensed to share-based compensation.

16. Stock options (continued)

The following table reflects the actual stock options issued and outstanding as of June 30, 2021:

Expiry date	Exercise price (\$)	Weighted average remaining contractual life (years)	Number of options outstanding	Number of options vested (exercisable)	
January 9, 2023	0.375	1.53	1,646,400	1,646,400	
February 18, 2024	0.12	2.64	600,000	600,000	
February 28, 2024	0.75	2.67	600,000	600,000	
February 28, 2024	0.25	2.67	4,560,000	4,560,000	
February 28, 2024	0.75	2.67	3,013,332	3,013,332	
June 3, 2024	0.15	2.93	1,850,000	1,850,000	
July 24, 2024	0.18	3.07	300,000	300,000	
October 4, 2024	0.15	3.27	3,300,000	3,300,000	
September 14, 2025	0.10	4.21	14,320,000	14,320,000	
October 7, 2025	0.10	4.27	200,000	200,000	
	0.22	3.43	30,389,732	30,389,732	

17. Warrants

	Number of warrants	Weighted average exercise price		
Balance, December 31, 2019 Issued (i)(ii) Expired	15,101,333 25,350,000 (3,000,000)	\$	0.18 0.05 0.15	
Balance, June 30, 2020	37,451,333	\$	0.10	
Balance, December 31, 2020 Issued (i) Expired Exercised	39,888,021 8,302,500 (1,000,000) (100,000)	\$	0.10 0.12 0.15 0.05	
Balance, June 30, 2021	47,090,521	\$	0.10	

(i) During the six months ended June 30, 2021, the Company issued an aggregate of 8,302,500 warrants (six months ended June 30, 2020 - 24,350,000 warrants) as a part of its non-brokered private placements. See note 15.

(ii) During the six months ended June 30, 2020, the Company issued 1,000,000 warrants to a certain creditor for loan extension. Each warrant was exercisable into one common share at a price of \$0.15 per share and expired on January 30, 2021. The fair value of \$25,000 was assigned to the warrants and has been estimated using the Black-Scholes model for pricing options under the following assumptions: risk free interest rate - 0.32%; dividend yield - 0%; expected stock volatility - 250% and an expected life of 8 months.

The following table reflects the warrants issued and outstanding as of June 30, 2021:

Expiry date	Exercise price (\$)	Warrants outstanding
September 30, 2021	0.15	6,700,000
July 20, 2022	0.15	250,000
September 17, 2022	0.15	161,688
November 15, 2022	0.30	2,001,333
November 30, 2022	0.20	500,000
December 13, 2022	0.20	2,400,000
December 23, 2022	0.20	125,000
December 24, 2022	0.10	2,100,000
January 8, 2023	0.10	5,700,000
April 30, 2023	0.05	9,600,000
May 22, 2023	0.05	6,000,000
June 17, 2023	0.05	7,400,000
November 3, 2023	0.10	550,000
July 30, 2024	0.18	1,000,000
April 9, 2023	0.15	1,946,250
April 30, 2023	0.15	656,250
	0.10	47,090,521

18. Related party balances and transactions

Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. The following related party transactions were conducted in the normal course of operations and were made on an arm's length basis:

	 Three Months Ended June 30, 2021		Three Months Ended June 30, 2020		Six Months Ended June 30, 2021		Six Months Ended June 30, 2020	
Consulting Professional fees Share-based compensation	\$ 75,000 16,986 -	\$	60,996 27,463 21,198	\$	112,500 28,047 -	\$	116,763 38,519 79,651	
	\$ 91,986	\$	109,657	\$	140,547	\$	234,933	

As at June 30, 2021, \$180,393 (December 31, 2020 - \$79,237) included in accounts payable and accrued liabilities was payable to key management personnel.

During the six months ended June 30, 2021, a director of the Company advanced \$45,000 to the Company. The advance is non-interest bearing and repayable on demand.

During the six months ended June 30, 2021, Budd Hutt advanced \$42,943 to the Company. The advance is non-interest bearing and repayable on demand.

19. Loss per share

For the three and six months ended June 30, 2021, basic and diluted loss per share has been calculated based on the loss attributable to common shares of \$674,304 and \$1,195,735, respectively (three and six months ended June 30, 2020 - \$422,297 and \$1,259,839, respectively) and weighted average number of common shares outstanding of 266,278,424 and 262,485,018, respectively (three and six months ended June 30, 2020 - 204,574,407 and 195,486,172, respectively). Diluted loss per share did not include the effect of stock options as they are anti-dilutive.

20. Subsequent events

In August 2021, the Company obtained a \$225,000 secured loan from Quinsam Capital Corporation ("Quinsam"). The loan is repayable by December 31, 2021, bears interest at 10% per annum, and is secured by the Company's assets. In connection therewith, the Company issued 750,000 warrants to Quinsam. Each warrant is exercisable for one common share of the Company at a price of \$0.15 per share for a period of 2 years.

On August 11, 2021, the Company closed the first tranche of its non-brokered private placement, pursuant to which it issued an aggregate of 9,044,142 units for gross proceeds of \$633,090. Each unit consists of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share of the Company at a price of \$0.15 per share for a period of 2 years.